Cover Image
市場調查報告書

C型肝炎:市場預測與分析

Hepatitis C disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 365202
出版日期 內容資訊 英文 441 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎:市場預測與分析 Hepatitis C disease forecast and market analysis to 2035
出版日期: 2017年03月16日 內容資訊: 英文 441 Pages
簡介

本報告提供C型肝炎治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:C型肝炎

  • 摘要整理
  • 市場概要·趨勢
  • 市場定義·調查手法
  • Daklinza (daclatasvir)
  • glecaprevir/pibrentasvir
  • Harvoni (sofosbuvir/ledipasvir)
  • Olysio (simeprevir)
  • sofosbuvir/velpatasvir
  • sofosbuvir/velpatasvir/GS-9857
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir)
  • Technivie (paritaprevir/ritonavir/ombitasvir)
  • Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
  • Zepatier (grazoprevir/elbasvir)
  • 主要調查手法

治療:C型肝炎

  • 摘要整理
  • 主要調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 各國治療系統
  • 處方趨勢
  • 未滿足需求

流行病學:美國·日本·EU5個國家的C型肝炎

  • 摘要整理
  • 疾病的背景
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制
  • 附錄

上市藥:C型肝炎

  • 摘要整理
  • 產品概要
  • 產品簡介:Daklinza
  • 產品簡介:Harvoni
  • 產品簡介:Olysio
  • 產品簡介:Sovaldi
  • 產品簡介:Sunvepra
  • 產品簡介:Viekira Pak
  • 產品簡介:Zepatier

與價格償付:C型肝炎

  • 摘要整理
  • 市場背景
  • 美國
  • 日本
  • EU5個國家

開發平台:C型肝炎

  • 摘要整理
  • 臨床開發平台概要
  • 初期階段的機會
  • 產品簡介 (後期階段) :DCV-TRIO
  • 產品簡介 (開發後期) :glecaprevir/pibrentasvir
  • 產品簡介 (開發後期) :sofosbuvir/velpatasvir/voxilaprevir

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5260

Disease Overview

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridae virus family and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease. Approximately 15% of infected individuals are able to clear the virus and are free from associated complications. The remaining 85% of individuals are at risk of chronic hepatitis and complications associated with chronic infection, such as scarring, liver cancer, and liver failure. An estimated 20-30% of chronic HCV patients go on to develop cirrhosis, while 1-5% will develop liver cancer.

Table of Contents (Full Disease Coverage)

FORECAST: HEPATITIS C

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • Daklinza (daclatasvir)
  • glecaprevir/pibrentasvir
  • Harvoni (sofosbuvir/ledipasvir)
  • Olysio (simeprevir)
  • sofosbuvir/velpatasvir
  • sofosbuvir/velpatasvir/GS-9857
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir)
  • Technivie (paritaprevir/ritonavir/ombitasvir)
  • Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
  • Zepatier (grazoprevir/elbasvir)
  • Primary Research Methodology

TREATMENT: HEPATITIS C

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Country Treatment Trees
  • Prescribing Trends
  • Unmet Needs in Hepatitis C

EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU

  • Executive Summary
  • Disease Overview
  • Sources and Methodology
  • Forecast
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix

MARKETED DRUGS: HEPATITIS C

  • Executive Summary
  • Product Overview
  • Product profile: Daklinza
  • Product profile: Epclusa
  • Product profile: Harvoni
  • Product profile: Olysio
  • Product profile: Sovaldi
  • Product profile: Sunvepra
  • Product profile: Viekira Pak
  • Product profile: Zepatier

HEPATITIS C PRICING AND REIMBURSEMENT

  • Executive Summary
  • Market Context
  • US
  • Japan
  • Five Major EU Markets

PIPELINE: HEPATITIS C

  • Executive Summary
  • Clinical Pipeline Overview
  • Early-Phase Opportunities
  • Product profile (late stage): DCV-TRIO
  • Product profile (late stage): glecaprevir/pibrentasvir
  • Product profile (late stage): sofosbuvir/velpatasvir/voxilaprevir

LIST OF FUGURES

  • Figure 1: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 2: Hepatitis C market value in the US, by class, 2015-24
  • Figure 3: US hepatitis C sales of key brands, 2015-24
  • Figure 4: Chronic hepatitis C prevalence in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 5: Hepatitis C genotype 3 market value in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 6: Hepatitis C sales in the five major EU markets, by country, 2015-24
  • Figure 7: Hepatitis C sales of key brands in the five major EU markets, 2015-24
  • Figure 8: Hepatitis C market value in Japan, by class, 2015-24
  • Figure 9: Hepatitis C sales across the US, Japan, and five major EU markets, by company, 2015-24
  • Figure 10: Patient-based forecast methodology for hepatitis C
  • Figure 11: Methodology for adjusting the hepatitis C prevalent population for drug cure rates
  • Figure 12: Price sources and calculations, by country
  • Figure 13: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 14: Glecaprevir/pibrentasvir sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 16: Olysio sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 17: Sofosbuvir/velpatasvir sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 18: Sofosbuvir/velpatasvir/GS-9857 sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 20: Sunvepra sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 21: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 22: Viekira Pak sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 23: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 24: Percentage of chronic hepatitis C prevalent population who are diagnosed/undiagnosed, by country
  • Figure 25: Percentage of chronic hepatitis C prevalent population who are expected to be diagnosed/undiagnosed in five years' time, by country
  • Figure 26: Percentage of the hepatitis C-diagnosed population under physician care in the US, Japan, and five major EU markets, by country
  • Figure 27: Treatment status of hepatitis C patients under physician care in the US, Japan, and five major EU markets, by country
  • Figure 28: Breakdown of pharmacologically treated chronic hepatitis C patients in the US, Japan, and five major EU markets by line of therapy, by country
  • Figure 29: Top four regimens of each analyzed market used for the treatment of GT-1 first-line hepatitis C patients, by country
  • Figure 30: Top five brands of each analyzed market used for the treatment of GT-1 first-line hepatitis C patients, by country
  • Figure 31: Top four regimens of each analyzed market used for the treatment of GT-1 second-line hepatitis C patients, by country
  • Figure 32: Top five brands of each analyzed market used for the treatment of GT-1 second-line hepatitis C patients, by country
  • Figure 33: Top four regimens of each analyzed market used for the treatment of GT-2 first-line hepatitis C patients, by country
  • Figure 34: Top five brands of each analyzed market used for the treatment of GT-2 first-line hepatitis C patients, by country
  • Figure 35: Top four regimens of each analyzed market used for the treatment of GT-2 second-line hepatitis C patients, by country
  • Figure 36: Top five brands of each analyzed market used for the treatment of GT-2 second-line hepatitis C patients, by country
  • Figure 37: Top four regimens of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • Figure 38: Top five brands of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • Figure 39: Top four regimens of each analyzed market used for the treatment of GT-3 second-line hepatitis C patients, by country
  • Figure 40: Top five brands of each analyzed market used for the treatment of GT-3 second-line hepatitis C patients, by country
  • Figure 41: Top four regimens of each analyzed market used for the treatment of GT-4/5/6 first-line hepatitis C patients, by country
  • Figure 42: Top five brands of each analyzed market used for the treatment of GT-4/5/6 first-line hepatitis C patients, by country
  • Figure 43: Top four regimens of each analyzed market used for the treatment of GT-4/5/6 second-line hepatitis C patients, by country
  • Figure 44: Top five brands of each analyzed market used for the treatment of GT-4/5/6 second-line hepatitis C patients, by country
  • Figure 45: Methodology for adjusting hepatitis C prevalent population for drug cure rates
  • Figure 46: Trends in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 47: Absolute growth in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 48: Trends in total Hepatitis C prevalent cases after adjusting for treatment and cure in the US, Japan, and five major EU markets , by country, 2015-35
  • Figure 49: Absolute growth in total Hepatitis C prevalent cases after adjusting for treatment and cure in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 50: Daklinza for hepatitis C - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C

LIST OF TABLES

  • Figure 53: Epclusa for hepatitis C - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • Figure 56: Harvoni for hepatitis C - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • Figure 59: Olysio for hepatitis C - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Olysio for hepatitis C
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Olysio for hepatitis C
  • Figure 62: Sovaldi for hepatitis C - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • Figure 65: Sunvepra for hepatitis C - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Sunvepra for hepatitis C
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Sunvepra for hepatitis C
  • Figure 68: Viekira Pak for hepatitis C - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Viekira Pak for hepatitis C
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Viekira Pak for hepatitis C
  • Figure 71: Zepatier for hepatitis C - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • Figure 74: RG-101 for hepatitis C - SWOT analysis
  • Figure 75: DCV-TRIO for hepatitis C - SWOT analysis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of DCV-TRIO for hepatitis C
  • Figure 77: Datamonitor Healthcare's drug assessment summary of DCV-TRIO for hepatitis C
  • Figure 78: Glecaprevir/pibrentasvir for hepatitis C - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of glecaprevir/pibrentasvir for hepatitis C
  • Figure 80: Datamonitor Healthcare's drug assessment scores and weightings for glecaprevir/pibrentasvir for hepatitis C
  • Figure 81: Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C - SWOT analysis
  • Figure 82: Datamonitor Healthcare's drug assessment summary of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
  • Figure 83: Datamonitor Healthcare's drug assessment summary of sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
  • Table 1: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 2: Hepatitis C market value in the US, by class ($m), 2015-24
  • Table 3: US hepatitis C sales of key brands ($m), 2015-24
  • Table 4: Chronic hepatitis C prevalence in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 5: Hepatitis C genotype 3 market value in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 6: Hepatitis C sales in the five major EU markets, by country ($m), 2015-24
  • Table 7: Hepatitis C sales of key brands in the five major EU markets ($m), 2015-24
  • Table 8: Hepatitis C market value in Japan, by class ($m), 2015-24
  • Table 9: Hepatitis C sales across the US, Japan, and five major EU markets, by company ($m), 2015-24
  • Table 10: Hepatitis C market value across the US, Japan, and five major EU markets, by brand and class ($m), 2015-24
  • Table 11: Summary of drug classes and molecules in Datamonitor Healthcare's hepatitis C patient-based forecast
  • Table 12: Exchange rates used for calculating prices
  • Table 13: Estimated launch dates for key late-stage hepatitis C pipeline candidates in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 14: Daklinza price and dose assumptions, by country
  • Table 15: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 16: Glecaprevir/pibrentasvir price and dose assumptions, by country
  • Table 17: Glecaprevir/pibrentasvir sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 18: Harvoni price and dose assumptions, by country
  • Table 19: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 20: Olysio price and dose assumptions, by country
  • Table 21: Olysio sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 22: Sofosbuvir/velpatasvir price and dose assumptions, by country
  • Table 23: Sofosbuvir/velpatasvir sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 24: Sofosbuvir/velpatasvir/GS-9857 price and dose assumptions, by country
  • Table 25: Sofosbuvir/velpatasvir/GS-9857 sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 26: Sovaldi price and dose assumptions, by country
  • Table 27: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 28: Sunvepra price and dose assumptions, by country
  • Table 29: Sunvepra sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 30: Technivie price and dose assumptions, by country
  • Table 31: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 32: Viekira Pak price and dose assumptions, by country
  • Table 33: Viekira Pak sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 34: Zepatier price and dose assumptions, by country
  • Table 35: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 36: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2015
  • Table 37: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2015
  • Table 38: Estimated chronic hepatitis C prevalence, by region, 2015
  • Table 39: Interpretation of results from hepatitis C screening assays
  • Table 40: Prevalence of hepatitis C by genotype across the US, Japan, and five major EU markets, by country, 2015
  • Table 41: METAVIR fibrosis scores of under care patients in the US, Japan, and five major EU markets, by country
  • Table 42: Reasons for not receiving treatment in the US, Japan, and five major EU markets, by country
  • Table 43: Treatments available for hepatitis C across the US, Japan, and five major EU markets
  • Table 44: Summary of "recommended" treatment options for newly diagnosed patients in AASLD and EASL treatment guidelines
  • Table 45: Relative importance of unmet needs in hepatitis C treatment in the US, Japan, and five major EU markets, by country
  • Table 46: Sources used for hepatitis C analysis in the US, Japan, and five major EU markets
  • Table 47: Notable population-based sources not used for hepatitis C analysis in the US, Japan, and five major EU markets
  • Table 48: Total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 49: Age-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2015
  • Table 50: Gender-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2015
  • Table 51: Prevalence of hepatitis C by genotype across the US, Japan, and five major EU markets, by country, 2015
  • Table 52: Segmentation of hepatitis C patient population by genotype across the US, Japan, and five major EU markets, by country, 2015
  • Table 53: Treatment- and cure-adjusted total prevalent cases of Hepatitis C in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 54: Key marketed drugs for hepatitis C
  • Table 55: Daklinza drug profile
  • Table 56: Pivotal studies supporting approvals of Daklinza
  • Table 57: Epclusa drug profile
  • Table 58: Pivotal studies supporting approvals of Epclusa for hepatitis C
  • Table 59: Epclusa late-phase trial data in hepatitis C
  • Table 60: Epclusa ongoing late-phase trials in hepatitis C
  • Table 61: Harvoni drug profile
  • Table 62: Pivotal studies supporting approvals of Harvoni
  • Table 63: Olysio drug profile
  • Table 64: Pivotal studies supporting approvals of Olysio
  • Table 65: Olysio ongoing trials in hepatitis C
  • Table 66: Sovaldi drug profile
  • Table 67: Pivotal studies supporting approvals of Sovaldi
  • Table 68: Sunvepra drug profile
  • Table 69: Pivotal studies supporting approval of Sunvepra
  • Table 70: Viekira Pak drug profile
  • Table 71: Pivotal studies supporting approvals of Viekira Pak
  • Table 72: Viekira Pak late-phase trial data in hepatitis C
  • Table 73: Zepatier drug profile
  • Table 74: Pivotal studies supporting approvals of Zepatier
  • Table 75: Zepatier late-phase trial data in hepatitis C
  • Table 76: Marketed hepatitis C products and approved indications in the US, Japan, and five major EU markets
  • Table 77: Late-stage candidates in development for hepatitis C
  • Table 78: Price sources and calculations, by country
  • Table 79: Exchange rates used for calculating prices
  • Table 80: US pricing of key hepatitis C regimens using Harvoni, Incivek, Olysio, Sovaldi, Victrelis, and Viekira Pak
  • Table 81: Cost per sustained virologic response for Harvoni, Incivek, Olysio, Sovaldi, Victrelis, and Viekira Pak
  • Table 82: Number of diagnosed and undiagnosed HCV-infected individuals, by insurance coverage, 2014, 2017, and 2020
  • Table 83: Formulary placement of Harvoni, Olysio, Sovaldi, Victrelis, and Viekira Pak in selected commercial formularies
  • Table 84: Formulary placement of Harvoni, Olysio, Sovaldi, Victrelis, and Viekira Pak in top five 2015 Medicare Part D formularies
  • Table 85: Prior authorization criteria for Harvoni, Olysio, Sovaldi, Victrelis, and Viekira Pak in four major health plans
  • Table 86: Japan - pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 87: Pricing of key hepatitis C regimens using Daklinza/Sunvepra, Sovriad, Telavic, and Vanihep in Japan
  • Table 88: Pricing of key hepatitis C regimens using Daklinza, Incivek, Olysio, Sovaldi, and Victrelis in the five major EU markets
  • Table 89: Transparency Commission's ASMR ratings and pricing implications
  • Table 90: Transparency Commission's assessment of hepatitis C treatments
  • Table 91: G-BA assessment of key HCV therapies
  • Table 92: NICE assessments of key HCV therapies
  • Table 93: SMC decisions on key HCV therapies
  • Table 94: Phase III pipeline products in development for chronic hepatitis C infection
  • Table 95: Select drugs in early-stage development for hepatitis C
  • Table 96: DCV-TRIO drug profile
  • Table 97: Key Phase III studies of DCV-TRIO in hepatitis C
  • Table 98: Glecaprevir/pibrentasvir drug profile
  • Table 99: Pivotal Phase III studies of glecaprevir/pibrentasvir in hepatitis C
  • Table 100: Glecaprevir/pibrentasvir ongoing Phase III trials in hepatitis C
  • Table 101: Sofosbuvir/velpatasvir/voxilaprevir drug profile
  • Table 102: Pivotal Phase III trials of sofosbuvir/velpatasvir/voxilaprevir for chronic hepatitis C infection
Back to Top